Replies to post #211017 on Biotech Values

[DewDiligence]

For AZN, Imfinzi’s big test lies ahead—the MYSTIC trial in first-line NSCLC, where results are due in a few months (#msg-130878440).

Reuters piece on today’s FDA accelerated approval in bladder cancer:
http://www.reuters.com/article/us-astrazeneca-fda-idUSKBN17X22Y